智飞生物(300122) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥2,704,787,498.73, a decrease of 40.26% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥601,112,699.06, representing a decline of 556.79% year-on-year[3]. - The company reported a basic earnings per share of -¥0.2511, a decrease of 556.79% year-on-year[3]. - The company’s operating income for the year-to-date was ¥7,627,406,876.36, down 66.53% from the previous year[9]. - Total revenue for the current period is ¥7,627,406,876.36, a decrease of 66.6% compared to ¥22,786,387,624.05 in the previous period[18]. - The net profit for the current period is a loss of ¥1,219,476,713.57, compared to a profit of ¥2,093,999,456.09 in the previous period[19]. - The company reported a basic and diluted earnings per share of -0.5040, down from 0.8864 in the previous period[19]. Cash Flow - The net cash flow from operating activities reached ¥2,985,018,894.57, an increase of 201.18% compared to the previous year[3]. - The net cash flow from financing activities was -¥2,754,297,064.98, a decrease of 471.81% compared to the previous year, mainly due to increased loan repayments[10]. - The net cash flow from operating activities was CNY 2,985,018,894.57, a significant improvement compared to the previous period's negative cash flow of CNY -2,950,190,022.15[21]. - Total cash inflow from operating activities decreased to CNY 11,125,790,912.40 from CNY 28,722,137,303.55, representing a decline of approximately 61.2%[21]. - Cash outflow from operating activities also decreased to CNY 8,140,772,017.83 from CNY 31,672,327,325.70, a reduction of about 74.3%[21]. - The net cash flow from investing activities was CNY -439,564,883.74, an improvement from CNY -869,989,167.77 in the previous period[21]. - Cash inflow from financing activities increased to CNY 13,003,450,918.54 from CNY 10,349,312,326.46, marking an increase of approximately 25.4%[21]. - Cash outflow from financing activities rose to CNY 15,757,747,983.52 from CNY 9,608,538,204.40, an increase of about 64.0%[21]. - The cash and cash equivalents at the end of the period decreased to CNY 2,494,818,737.62 from CNY 3,262,918,108.95, a decline of approximately 23.5%[22]. - The company’s cash and cash equivalents net increase was CNY -209,250,629.34, a significant improvement from CNY -3,080,206,481.13 in the previous period[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥46,392,433,396.07, down 9.50% from the end of the previous year[3]. - Total current assets at the end of the reporting period amount to 36,113,056,421.78 RMB, down from 41,368,956,194.55 RMB at the beginning of the period, representing a decrease of approximately 12.5%[15]. - The company's total assets decreased to ¥46,392,433,396.07 from ¥51,261,907,524.36, a decline of 9.5%[17]. - Current liabilities decreased significantly to ¥12,884,692,048.47 from ¥18,850,993,178.50, a reduction of 31.6%[17]. - The company's total liabilities decreased to ¥16,785,730,973.03 from ¥20,435,728,387.75, a decline of 17.9%[17]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 131,557[12]. - Major shareholder Jiang Rensheng holds 48.44% of shares, totaling 1,159,573,500 shares, with 184,700,000 shares pledged[12]. - The company has a total of 289,893,375 unrestricted shares held by major shareholder Jiang Rensheng[13]. - The number of shareholders with voting rights restored for preferred shares is 0[12]. Other Notable Changes - The company experienced a significant increase in other receivables, which rose by 4238.76% to ¥475,804,737.80 due to payments made to suppliers[7]. - The company’s long-term borrowings increased by 149.11% to ¥3,094,161,871.06, primarily due to new bank loans[8]. - The company reported a significant increase in government subsidies recognized in profit or loss, which rose by 43.01% to ¥27,833,751.77[9]. - The company has made significant investments in intangible assets, with a current balance of ¥639,787,556.50, up from ¥346,246,140.47, indicating a focus on technology and data resources[17]. - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending[14]. - The company has not disclosed any new product developments or market expansion strategies in the current report[14]. - There are no significant changes in the status of restricted shares or any new mergers and acquisitions reported[14].